Notices. Notification of withdrawal
553 words·~3 min read·
/register/2021/02/23/2021-03250·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
BILLING CODE 4164-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration 21 CFR Parts 510, 520, and 522 [Docket No. FDA-2019-N-5405] New Animal Drugs; Withdrawal of Approval of New Animal Drug Applications AGENCY: Food and Drug Administration, HHS. ACTION: Notification of withdrawal. SUMMARY: The Food and Drug Administration
(FDA)is withdrawing approval of seven new animal drug applications (NADAs) from multiple holders of these applications. The basis for the withdrawals is that the holders of these applications have repeatedly failed to file required annual reports for the applications. DATES: Withdrawal of approval is effective February 23, 2021. FOR FURTHER INFORMATION CONTACT: David Alterman, Center for Veterinary Medicine (HFV-212), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-402-5720, *david.alterman@fda.hhs.gov.* SUPPLEMENTARY INFORMATION: The holders of approved applications to market new animal drugs are required to submit annual reports to FDA concerning each of their approved applications in accordance with § 514.80 (21 CFR 514.80). In the **Federal Register** of January 8, 2020 (85 FR 919), FDA published a notice offering an opportunity for a hearing
(NOOH)on a proposal to withdraw approval of seven NADAs because the sponsors had failed to submit the required annual reports for these applications. The holders of these applications did not respond to the NOOH. Failure to file a written notice of participation and request for a hearing as required by § 514.200(b) (21 CFR 514.200(b)) constitutes an election by the applicant not to make use of the opportunity for a hearing concerning the proposal to withdraw approval of the applications and a waiver of any contentions concerning the legal status of the drug products. Therefore, approval of the seven applications listed in table 1 is being withdrawn. Table 1—NADAs for Which Approval Is Withdrawn Application No. Trade name
(drug)Sponsor 031-971 CUPRATE (cupric glycinate) Walco International, Inc., 15 West Putnam, Porterville, CA 93257. 045-863 PALOSEIN (orgotein) OXIS International, Inc., 6040 N. Cutter Circle, suite 317, Portland, OR 97217-3935. 046-922 SERGEANTS SURE SHOT ( *n-* butyl chloride) Capsules ConAgra Pet Products Co., 3902 Leavenworth St., Omaha, NE 68105. 046-923 SERGEANTS ( *n* -butyl chloride) Puppy Worm Capsules ConAgra Pet Products Co., 3902 Leavenworth St., Omaha, NE 68105. 065-067 Tetracycline Hydrochloride Tablets Premo Pharmaceutical Laboratories, Inc., 111 Leuning St., South Hackensack, NJ 07606. 140-850 ELITE (dichlorophene and toluene) Dog and Cat Wormer RSR Laboratories, Inc., 501 Fifth St., Bristol, TN 37620. 141-107 BAPTEN for Injection (ß-aminopropionitrile fumarate) Alaco, Inc., 1500 North Wilmot Rd., suite 290-C, Tucson, AZ 85712. The Commissioner of Food and Drugs (the Commissioner), under section 512(e)(2)(A) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b(e)(2)(A)), finds that the holders of the applications listed in this document have repeatedly failed to submit reports required by § 514.80. In addition, under § 514.200(b), the Commissioner finds that the holders of the applications have waived any contentions concerning the legal status of the drug products. Therefore, under these findings, approval of the applications listed in this document, and all amendments and supplements thereto, is hereby withdrawn, effective February 23, 2021. Elsewhere in this issue of the **Federal Register** *,* FDA is amending the animal drug regulations to reflect the withdrawal of approval of these applications. Dated: February 11, 2021. Lauren K. Roth, Acting Principal Associate Commissioner for Policy. [FR Doc. 2021-03250 Filed 2-22-21; 8:45 am]
Connectionstraces to 3
Citation graph
cites case law
Cites 3Cited by 0 across 0 sources